The SGLT2 inhibitors dapagliflozin and empagliflozin are pillars of therapy for HFrEF, based on the important DAPA‐HF (Dapagliflozin And Prevention of Adverse‐outcomes in HF) trial94, 95 and the EMPEROR‐Reduced (Empagliflozin Outcome Trial in Patients with Chronic HF and a Reduced Ejection Fraction) trial.96 Here, SLC5A2 is linked to hydrops fetalis.